ZA200103946B - A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state. - Google Patents
A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state.Info
- Publication number
- ZA200103946B ZA200103946B ZA200103946A ZA200103946A ZA200103946B ZA 200103946 B ZA200103946 B ZA 200103946B ZA 200103946 A ZA200103946 A ZA 200103946A ZA 200103946 A ZA200103946 A ZA 200103946A ZA 200103946 B ZA200103946 B ZA 200103946B
- Authority
- ZA
- South Africa
- Prior art keywords
- meta
- particles
- producing particles
- amorphous
- crystalline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Oxygen, Ozone, And Oxides In General (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Recrystallisation Techniques (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9804000A SE9804000D0 (sv) | 1998-11-23 | 1998-11-23 | New composition of matter |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200103946B true ZA200103946B (en) | 2002-10-30 |
Family
ID=20413377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200103946A ZA200103946B (en) | 1998-11-23 | 2001-05-15 | A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state. |
Country Status (27)
Country | Link |
---|---|
US (1) | US6475524B1 (cs) |
EP (1) | EP1133285B1 (cs) |
JP (1) | JP4447169B2 (cs) |
KR (1) | KR100697780B1 (cs) |
CN (1) | CN1198592C (cs) |
AT (1) | ATE318583T1 (cs) |
AU (1) | AU767313B2 (cs) |
BR (1) | BR9915592A (cs) |
CA (1) | CA2349633C (cs) |
CY (1) | CY1105609T1 (cs) |
CZ (1) | CZ20011778A3 (cs) |
DE (1) | DE69930158T2 (cs) |
DK (1) | DK1133285T3 (cs) |
EE (1) | EE200100275A (cs) |
ES (1) | ES2258865T3 (cs) |
HU (1) | HUP0104182A2 (cs) |
IL (2) | IL143040A0 (cs) |
IS (1) | IS5946A (cs) |
NO (1) | NO20012514L (cs) |
NZ (1) | NZ511494A (cs) |
PL (1) | PL348523A1 (cs) |
PT (1) | PT1133285E (cs) |
SE (1) | SE9804000D0 (cs) |
SK (1) | SK7032001A3 (cs) |
TR (1) | TR200101424T2 (cs) |
WO (1) | WO2000030614A1 (cs) |
ZA (1) | ZA200103946B (cs) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0016002D0 (en) * | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
DE10062712A1 (de) * | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden |
CA2433169A1 (en) * | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Porous substances and methods for producing the same |
WO2003004142A1 (en) * | 2001-07-02 | 2003-01-16 | Micro & Nano Materials Sagl | Process for the production of micro and/or nano particles |
GB0126716D0 (en) * | 2001-11-07 | 2002-01-02 | Advanced Phytonics Ltd | Method for the production of particles |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
JP2007520509A (ja) * | 2004-02-06 | 2007-07-26 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト | 抗コリン薬による、又は抗ヒスタミン薬、ホスホジエステラーゼ4、又はコルチコステロイドとの組み合わせによる鼻炎治療薬 |
TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
US7498445B2 (en) | 2004-05-05 | 2009-03-03 | Renopharm Ltd. | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof |
US7968575B2 (en) | 2004-05-05 | 2011-06-28 | Renopharm Ltd. | Nitric oxide donors and uses thereof |
US8134010B2 (en) | 2004-05-05 | 2012-03-13 | Renopharm Ltd. | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof |
WO2005105065A2 (en) | 2004-05-05 | 2005-11-10 | Renopharm Ltd. | Thiazole-based nitric oxide donors for treating inflammatory bowel diseases |
WO2006023460A2 (en) | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
JP5000095B2 (ja) * | 2005-03-11 | 2012-08-15 | 花王株式会社 | 有機結晶粒子の製造方法 |
EP1904219A4 (en) | 2005-07-15 | 2011-07-27 | Map Pharmaceuticals Inc | METHOD FOR FORMING PARTICLES |
DE102006030166A1 (de) * | 2006-06-29 | 2008-01-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tempern |
WO2009047935A1 (ja) * | 2007-10-12 | 2009-04-16 | Ono Pharmaceutical Co., Ltd. | 微粒子 |
US8585943B2 (en) * | 2007-12-07 | 2013-11-19 | Xspray Microparticles Ab | Method and arrangement for the production of particles |
JP5138670B2 (ja) * | 2009-01-30 | 2013-02-06 | 三洋化成工業株式会社 | 樹脂粒子およびその製造方法 |
EP3620154A1 (en) | 2009-02-06 | 2020-03-11 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
EP2453894B1 (en) | 2009-07-15 | 2015-11-04 | Theravance Biopharma R&D IP, LLC | Crystalline freebase form of a biphenyl compound |
BR112012022209A2 (pt) | 2010-03-03 | 2017-06-06 | Neonc Tech Inc | composições farmacêuticas compreendendo monoterpenos |
US20160038600A1 (en) | 2012-08-03 | 2016-02-11 | Neonc Technologies Inc. | Pharmaceutical compositions comprising poh derivatives |
BR112013004698B1 (pt) | 2010-08-27 | 2022-03-22 | Neonc Technologies Inc. | Composições farmacêuticas compreendendo derivados de poh |
CN103517892B (zh) | 2010-12-17 | 2016-01-27 | 尼昂克技术公司 | 使用异紫苏醇的方法和装置 |
JP6560986B2 (ja) | 2013-03-15 | 2019-08-14 | ヴェローナ ファーマ ピーエルシー | 複合製剤 |
GB201402556D0 (en) | 2014-02-13 | 2014-04-02 | Crystec Ltd | Improvements relating to inhalable particles |
RU2688191C2 (ru) | 2014-05-12 | 2019-05-21 | ВЕРОНА ФАРМА ПиэЛСи | Новое лечение |
KR20170131405A (ko) | 2015-02-12 | 2017-11-29 | 네온씨 테크놀로지스, 아이엔씨. | 페릴릴 알코올 유도체를 포함하는 의약 조성물 |
CN110267538B (zh) | 2016-11-30 | 2022-04-19 | 尼昂克技术公司 | 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法 |
EP4389765A2 (en) | 2018-02-08 | 2024-06-26 | University of Southern California | Methods of permeabilizing the blood brain barrier |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
SE9101090D0 (sv) | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
US5639441A (en) * | 1992-03-06 | 1997-06-17 | Board Of Regents Of University Of Colorado | Methods for fine particle formation |
GB9313642D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
GB9413202D0 (en) * | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
ATE212545T1 (de) * | 1995-03-28 | 2002-02-15 | Fidia Advanced Biopolymers Srl | Nanosphären mit einem biokompatiblen polysaccharid |
CN100548277C (zh) | 1997-03-20 | 2009-10-14 | 先灵公司 | 粉末附聚物的制备方法 |
-
1998
- 1998-11-23 SE SE9804000A patent/SE9804000D0/xx unknown
-
1999
- 1999-11-22 US US09/486,675 patent/US6475524B1/en not_active Expired - Fee Related
- 1999-11-22 KR KR1020017006444A patent/KR100697780B1/ko not_active IP Right Cessation
- 1999-11-22 CZ CZ20011778A patent/CZ20011778A3/cs unknown
- 1999-11-22 CN CNB998136093A patent/CN1198592C/zh not_active Expired - Fee Related
- 1999-11-22 TR TR2001/01424T patent/TR200101424T2/xx unknown
- 1999-11-22 ES ES99963731T patent/ES2258865T3/es not_active Expired - Lifetime
- 1999-11-22 PT PT99963731T patent/PT1133285E/pt unknown
- 1999-11-22 EP EP99963731A patent/EP1133285B1/en not_active Expired - Lifetime
- 1999-11-22 DE DE69930158T patent/DE69930158T2/de not_active Expired - Lifetime
- 1999-11-22 IL IL14304099A patent/IL143040A0/xx unknown
- 1999-11-22 WO PCT/SE1999/002154 patent/WO2000030614A1/en active IP Right Grant
- 1999-11-22 JP JP2000583498A patent/JP4447169B2/ja not_active Expired - Fee Related
- 1999-11-22 PL PL99348523A patent/PL348523A1/xx not_active Application Discontinuation
- 1999-11-22 AU AU20104/00A patent/AU767313B2/en not_active Ceased
- 1999-11-22 EE EEP200100275A patent/EE200100275A/xx unknown
- 1999-11-22 BR BR9915592-3A patent/BR9915592A/pt not_active Application Discontinuation
- 1999-11-22 AT AT99963731T patent/ATE318583T1/de not_active IP Right Cessation
- 1999-11-22 DK DK99963731T patent/DK1133285T3/da active
- 1999-11-22 CA CA002349633A patent/CA2349633C/en not_active Expired - Fee Related
- 1999-11-22 HU HU0104182A patent/HUP0104182A2/hu unknown
- 1999-11-22 SK SK703-2001A patent/SK7032001A3/sk unknown
- 1999-11-22 NZ NZ511494A patent/NZ511494A/en not_active IP Right Cessation
-
2001
- 2001-05-08 IL IL143040A patent/IL143040A/en not_active IP Right Cessation
- 2001-05-15 ZA ZA200103946A patent/ZA200103946B/xx unknown
- 2001-05-18 IS IS5946A patent/IS5946A/is unknown
- 2001-05-22 NO NO20012514A patent/NO20012514L/no not_active Application Discontinuation
-
2006
- 2006-05-17 CY CY20061100642T patent/CY1105609T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200103946B (en) | A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state. | |
NZ514574A (en) | Novel method of treatment | |
WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
WO2001041761A3 (en) | Valdecoxib compositions | |
CA2339221A1 (en) | Extracts of feverfew (tanacetum parthenium) against inflammatory disorders | |
CA2366268A1 (en) | Pharmaceutical compositions for cns and other disorders | |
WO1996015786A3 (en) | Oral compositions containing ondansetron | |
BG104476A (en) | Therapeutical form for tolterodin with controlled release | |
WO2003024387A3 (en) | Method and pharmaceutical composition for treating inflammation | |
HUT60630A (en) | Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature | |
CA2306393A1 (en) | Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization | |
CA2330480A1 (en) | Controlled release formulation of divalproex sodium | |
CA2198706A1 (en) | Methods for the treatment of inflammatory joint disease | |
WO2001001974A3 (en) | Naaladase inhibitors in anxiety and memory disorders | |
NO962752L (no) | Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose | |
CA2282279A1 (en) | Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions | |
CA2501738A1 (en) | Method of treating chronic pelvic pain syndrome by administration of chrorionic gonadotropin | |
ZA906057B (en) | 4-(n-substituted amino)-2-butynyl-1-ureas and thioureas and derivatives thereof as centrally acting muscarinic agents | |
WO2001042272A3 (en) | Eplerenone crystalline form exhibiting enhanced dissolution rate | |
UA74388C2 (uk) | Фармацевтичні композиції тизоксаніду і нітазоксаніду | |
UA66932C2 (en) | Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine | |
CA2279943A1 (en) | Treatment of skin disorders | |
EP0743068A3 (en) | Composition for inhibiting bone loss containing vanadyl sulfate | |
WO2002076437A3 (en) | Methods for treating neurodegenerative diseases including alzheimer's | |
WO1999021005A3 (en) | Pharmaceutical grade st. john's wort |